



Understanding Peripartum Cardiomyopathy

¹Anjali Mehra, ²Dr. Gaurav Chaudhary,

¹Student, ²Assistant Professor,

¹Department Of Cardiovascular Technology,

¹Galgotias University, Greater Noida, India

Abstract: Peripartum cardiomyopathy (PPCM) poses a significant clinical challenge, presenting as heart failure in women during late pregnancy or postpartum. Despite medical advancements, PPCM diagnosis remains elusive due to its variable symptoms and absence of definitive criteria. This review comprehensively explores PPCM, spanning epidemiology, pathophysiology, clinical manifestations, diagnostic approaches, management strategies, and prognostic considerations. Enhanced understanding of PPCM complexities equips healthcare providers with the tools necessary for early identification, timely intervention, and improved outcomes, thereby underscoring the critical need for heightened awareness and multidisciplinary collaboration in managing this potentially life-threatening condition.

Index Terms - Component, formatting, style, styling, insert.

1.INTRODUCTION

Peripartum cardiomyopathy (PPCM) represents a rare but potentially devastating cardiovascular disorder that manifests as heart failure during the late stages of pregnancy or in the months following childbirth. While its exact etiology remains elusive, PPCM presents unique challenges to clinicians due to its variable presentation, which often mimics symptoms of normal pregnancy or other postpartum conditions. Despite advancements in medical science, PPCM continues to perplex healthcare providers, necessitating a deeper understanding of its epidemiology, pathophysiology, clinical features, diagnostic criteria, management strategies, and long-term outcomes.

This introduction sets the stage for a comprehensive exploration of PPCM, emphasizing the importance of elucidating its complexities to facilitate early recognition, appropriate intervention, and improved prognosis for affected women. By shedding light on the enigmatic nature of PPCM, this review aims to provide clinicians with valuable insights into navigating the diagnostic and therapeutic dilemmas posed by this condition, ultimately striving towards better care and outcomes for mothers facing this formidable challenge.

2.EPIDEMIOLOGY

Peripartum cardiomyopathy (PPCM) is a rare but potentially life-threatening condition characterized by the development of heart failure towards the end of pregnancy or in the months following delivery. The exact cause of PPCM is not fully understood, but it is believed to involve a combination of genetic predisposition, hormonal factors, and cardiovascular stressors associated with pregnancy.

In terms of epidemiology, PPCM affects approximately 1 in 1,000 to 1 in 4,000 pregnancies worldwide. However, there are significant regional and ethnic variations in its incidence. Certain populations, such as those of African descent, have been found to have a higher risk of developing PPCM compared to others.

3.PATHOPHYSIOLOGY

The pathophysiology of peripartum cardiomyopathy (PPCM) remains incompletely understood, but several hypotheses have been proposed to explain its development. Here's an overview.

3.1 Hormonal Factors

Hormonal changes during pregnancy, particularly in the levels of prolactin, have been implicated in the pathogenesis of PPCM. Prolactin is known to promote myocardial angiogenesis and lactation. However, in some cases, it may lead to adverse effects on cardiac function, such as inducing cardiomyocyte apoptosis and impairing contractility.

3.2 Genetic Predisposition

There is evidence suggesting a genetic predisposition to PPCM in some women. Mutations in genes encoding proteins involved in cardiac remodeling, angiogenesis, or hormonal signaling pathways may contribute to the development of PPCM. Familial clustering of PPCM cases has been observed, further supporting a genetic component.

3.3 Immune System Dysregulation

Autoimmune mechanisms have also been implicated in the pathogenesis of PPCM. Some studies have reported the presence of autoantibodies targeting cardiac proteins, such as β 1-adrenergic receptors or cardiac troponin I, in women with PPCM. These autoantibodies may lead to inflammation, myocardial damage, and impaired cardiac function.

3.4 Oxidative Stress

Increased oxidative stress within the myocardium has been proposed as a potential contributing factor to PPCM. Oxidative stress can result from an imbalance between the production of reactive oxygen species (ROS) and antioxidant defense mechanisms. Excessive ROS can damage cellular components, including lipids, proteins, and DNA, leading to myocardial injury and dysfunction.

3.5 Inflammatory Processes

Inflammation may play a role in the pathogenesis of PPCM, with evidence of increased levels of pro-inflammatory cytokines in affected individuals. Inflammatory mediators can promote myocardial inflammation, fibrosis, and remodeling, contributing to the development of cardiomyopathy.

3.6 Vascular Dysfunction

Impaired vascular function, including endothelial dysfunction and microvascular rarefaction, may also contribute to the pathophysiology of PPCM. Reduced myocardial perfusion secondary to vascular abnormalities could lead to myocardial ischemia, inflammation, and subsequent myocardial dysfunction.

3.7 Environmental Factors

Environmental factors, such as exposure to toxins or infections, may trigger or exacerbate PPCM in susceptible individuals. However, the specific environmental triggers of PPCM remain poorly understood and require further investigation.

4. CLINICAL PRESENTATION

The clinical presentation refers to the signs and symptoms that are observed in a patient during a medical examination or assessment. It encompasses all aspects of the patient's physical, mental, and emotional health that are relevant to their condition. The clinical presentation can vary widely depending on the underlying cause of the patient's illness or injury, as well as their age, gender, and other individual factors. Healthcare professionals use their knowledge and expertise to interpret the clinical presentation and make an accurate diagnosis, which is essential for determining the most appropriate treatment plan for each patient. Therefore, understanding and recognizing the various elements of clinical presentation is crucial for effective healthcare delivery.

The clinical presentation can vary widely among individuals, but common symptoms and signs include,

- ✓ **Shortness of breath (dyspnea):** This is often the most prominent symptom and may worsen with exertion or when lying flat.
- ✓ **Fatigue and weakness:** Patients may feel unusually tired and have decreased exercise tolerance.
- ✓ **Edema:** Swelling of the legs, ankles, feet, or other parts of the body due to fluid retention.
- ✓ **Orthopnea:** Difficulty breathing while lying flat, often relieved by sitting up or propping oneself with pillows.
- ✓ **Paroxysmal nocturnal dyspnea:** Sudden onset of severe shortness of breath that awakens the patient from sleep.
- ✓ **Palpitations:** Sensation of rapid or irregular heartbeats.
- ✓ **Chest pain or discomfort:** This may occur due to associated myocardial ischemia or other cardiac complications.
- ✓ **Cough:** Often nonproductive but may be present due to pulmonary congestion.
- ✓ **Decreased urine output:** This may occur due to reduced cardiac output and poor kidney perfusion.
- ✓ **Fatigue and malaise:** Patients may feel generally unwell and have difficulty performing daily activities.

5. DIAGNOSIS PERIPARTUM CARDIOMYOPATHY

The diagnosis of peripartum cardiomyopathy (PPCM) involves a combination of clinical evaluation, imaging studies, laboratory tests, and exclusion of other possible causes of heart failure. Here are the key components of diagnosing PPCM.

5.1 Clinical Evaluation

Healthcare providers will take a detailed medical history and perform a physical examination to assess for signs and symptoms of heart failure. They will inquire about the onset and duration of symptoms, past medical history, medications, and any relevant family history.

5.2 Imaging Studies

Echocardiography: This is the primary imaging modality used to diagnose PPCM. Echocardiography can assess the size and function of the heart chambers, measure ejection fraction (a key parameter in diagnosing heart failure), and detect any structural abnormalities.

Electrocardiography (ECG): An ECG can help identify any conduction abnormalities or arrhythmias that may be present.

Chest X-ray: This may reveal signs of pulmonary congestion or cardiomegaly (enlargement of the heart).

5.3 Laboratory Tests

Blood tests: These may include a complete blood count, electrolyte levels, renal function tests, liver function tests, and cardiac biomarkers such as brain natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP). Elevated levels of these biomarkers can indicate heart failure.

Thyroid function tests: Thyroid dysfunction can contribute to heart failure symptoms and should be assessed.

5.4 Exclusion of Other Causes

It's important to rule out other potential causes of heart failure, such as preexisting heart disease (e.g., hypertrophic cardiomyopathy, valvular heart disease), myocarditis, pulmonary embolism, or other systemic illnesses.

6. MANAGEMENT

The management of PPCM focuses on optimizing maternal cardiac function, alleviating symptoms, and minimizing maternal and fetal risks. Treatment strategies may include standard heart failure therapies such as diuretics, angiotensin-converting enzyme inhibitors (ACEIs), beta-blockers, and aldosterone antagonists. In severe cases, mechanical circulatory support or heart transplantation may be necessary. Importantly, management should be tailored to individual patient characteristics, with close monitoring throughout pregnancy and the postpartum period.

6.1 Medical Therapy

Medications are a cornerstone of PPCM management and are aimed at reducing the workload on the heart, improving heart function, and managing symptoms. Commonly used medications may include,

- ✓ **Diuretics:** to reduce fluid retention and edema.
- ✓ **Angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs):** to improve heart function.
- ✓ **Beta-blockers:** to reduce heart rate and blood pressure, thus reducing the workload on the heart.
- ✓ **Anticoagulants:** to prevent blood clots, especially if there is atrial fibrillation or other indications.

6.2 Monitoring

Close monitoring of the mother's and baby's health is essential during pregnancy and postpartum. This may involve regular check-ups with healthcare providers, monitoring of vital signs, and periodic echocardiograms to assess heart function.

6.3 Supportive Therapy

In severe cases, patients may require additional supportive therapies such as supplemental oxygen, mechanical ventilation, or even temporary mechanical circulatory support devices like intra-aortic balloon pumps or ventricular assist devices.

6.4 Nutritional Support

A balanced diet is crucial for overall health and can support recovery from PPCM. Healthcare providers may recommend dietary modifications to manage fluid retention and maintain cardiovascular health.

6.5 Activity Restrictions

Patients with PPCM may need to restrict physical activity, especially during the acute phase of the condition. Gradual reintroduction of exercise may be recommended as the patient's condition improves.

6.7 Breastfeeding

The safety of breastfeeding while taking certain medications for PPCM should be discussed with healthcare providers. In some cases, medications may need to be adjusted to ensure the safety of breastfeeding.

7. PROGNOSIS OF PPCM

The prognosis of peripartum cardiomyopathy (PPCM) can vary widely depending on several factors, including the severity of the condition at the time of diagnosis, the promptness and effectiveness of treatment, the presence of complications, and individual patient characteristics such as age, overall health, and underlying risk factors. Here are some key points regarding the prognosis of PPCM:

7.1 Recovery

While PPCM can be a serious condition, many women with PPCM do recover with appropriate medical treatment and supportive care. The degree of recovery can vary, with some women experiencing partial or complete normalization of heart function over time.

7.2 Complications

PPCM can be associated with various complications, such as arrhythmias, thromboembolism (blood clots), and heart failure exacerbations. The presence of complications can impact prognosis and may require additional interventions or management strategies.

7.3 Recurrence

There is a risk of recurrence with subsequent pregnancies for women who have experienced PPCM in the past. The risk of recurrence varies among individuals and may be influenced by factors such as underlying cardiac function and the presence of specific risk factors.

7.4 Long-Term Heart Function

Even in cases where women with PPCM experience improvement in heart function and symptoms, long-term monitoring is important to assess for any signs of relapse or ongoing cardiac issues. Some individuals may have persistent mild impairment of heart function even after apparent recovery.

7.5 Mortality

While mortality rates for PPCM have improved with advances in medical treatment and management strategies, PPCM can still be associated with significant morbidity and mortality, especially in cases of severe or advanced heart failure. However, with appropriate medical care, many women can achieve favorable outcomes.

7.6 Quality of Life

The impact of PPCM on quality of life can vary among individuals, depending on factors such as the degree of recovery, presence of ongoing symptoms, and overall functional status. Some women may experience limitations in daily activities or emotional distress related to their diagnosis, while others may be able to resume normal activities and have a good quality of life.

7.7 Psychological Impact

Coping with a diagnosis of PPCM and its potential long-term implications can be challenging for patients and their families. Access to psychological support, counseling, and support groups can play an important role in helping individuals navigate the emotional aspects of living with PPCM.

8. BRIDGING RESEARCH AND CLINICAL PRACTICE

Translating research findings into clinical practice is essential for improving the care of women with PPCM. Strategies to bridge the gap between research and clinical application include,

- ✓ **Implementation Science:** Applying principles of implementation science to integrate evidence-based practices into routine clinical care settings, optimize healthcare delivery processes, and enhance patient outcomes.
- ✓ **Continuing Education:** Providing ongoing professional development opportunities for healthcare providers through conferences, workshops, and online resources can ensure up-to-date knowledge and skills in managing PPCM.
- ✓ **Clinical Pathways:** Developing standardized clinical pathways and algorithms for the diagnosis, risk stratification, and management of PPCM can streamline care delivery, reduce variability in practice, and promote adherence to best practices.
- ✓ **Multidisciplinary Collaboration:** Facilitating collaboration between obstetricians, cardiologists, maternal-fetal medicine specialists, neonatologists, and other relevant disciplines fosters comprehensive, patient-centered care for women with PPCM.

9. CONCLUSION

Peripartum cardiomyopathy represents a complex and multifaceted condition with significant implications for maternal and fetal health. Addressing the challenges posed by PPCM requires a concerted effort across various domains, including research, policy, clinical practice, and patient advocacy. By harnessing the collective expertise of healthcare providers, researchers, policymakers, and community stakeholders, we can advance our understanding of PPCM, improve diagnostic accuracy and therapeutic efficacy, and ultimately enhance outcomes for affected women and their families. It represents a complex interplay of genetic, hormonal, immunological, and environmental factors, posing diagnostic and therapeutic challenges for clinicians worldwide. By embracing a multidisciplinary approach, integrating advances in basic science, clinical research, and patient-centered care, we can strive towards improved outcomes and quality of life for women affected by PPCM. Through continued collaboration, innovation, and advocacy, we can pave the way for a future where PPCM is not only better understood and managed but ultimately prevented altogether.

10. REFERENCES

1. Arany Z, Elkayam U. Peripartum Cardiomyopathy. *Circulation Research*. 2016;118(3): 400-409. doi:10.1161/CIRCRESAHA.115.306393.
2. Bauersachs J, König T, van der Meer P, et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. *European Journal of Heart Failure*. 2019;21(7):827-843. doi:10.1002/ejhf.1493.
3. Bello N, Rendon IS, Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis. *Journal of the American College of Cardiology*. 2013;62(18):1715-1723. doi:10.1016/j.jacc.2013.07.076.
4. Hilfiker-Kleiner D, Sliwa K. Pathophysiology and epidemiology of peripartum cardiomyopathy. *Nature Reviews Cardiology*. 2014;11(6):364-370. doi:10.1038/nrcardio.2014.37.
5. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. *European Journal of Heart Failure*. 2017;19(9):1131-1141. doi:10.1002/ejhf.872.
6. van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. *Circulation*. 2010;121(20):2169-2175. doi:10.1161/CIRCULATIONAHA.109.931796.
7. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. *Mayo Clinic Proceedings*. 2005;80(12):1602-1606. doi:10.4065/80.12.1602.
8. Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. *Journal of the American College of Cardiology*. 2011;58(7):659-670. doi:10.1016/j.jacc.2011.03.047.
9. Goland S, Modi K, Bitar F, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. *Journal of Cardiac Failure*. 2009;15(8):645-650. doi:10.1016/j.cardfail.2009.03.004.
10. Haghikia A, Podewski E, Libhaber E, et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. *Basic Research in Cardiology*. 2013;108(4):366. doi:10.1007/s00395-013-0366-8.
11. McNamara DM, Elkayam U, Alharethi R, et al. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). *Journal of the American College of Cardiology*. 2015;66(8):905-914. doi:10.1016/j.jacc.2015.06.1309.
12. Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. *Journal of the American Medical Association*. 2000;283(9):1183-1188. doi:10.1001/jama.283.9.1183.
13. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. *European Journal of Heart Failure*. 2010;12(8):767-778. doi:10.1093/eurjhf/hfq120.
14. Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. *Circulation*. 2010;121(13):1465-1473. doi:10.1161/CIRCULATIONAHA.109.929646.

15. Hilfiker-Kleiner D, Haghikia A, Nonhoff J, et al. Peripartum cardiomyopathy: current management and future perspectives. *European Heart Journal*. 2015;36(18):1090-1097. doi:10.1093/eurheartj/ehv009.
16. Elkayam U. Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy. *Journal of the American College of Cardiology*. 2014;64(15):1629-1636. doi:10.1016/j.jacc.2014.07.973.
17. Fett JD. Peripartum cardiomyopathy: a puzzle closer to solution. *Journal of Cardiac Failure*. 2010;16(7):593-595. doi:10.1016/j.cardfail.2010.04.004.
18. Desplantie O, Tremblay-Gravel M, Avram R, et al. Exercise capacity in peripartum cardiomyopathy. *Journal of Cardiac Failure*. 2018;24(3):163-168. doi:10.1016/j.cardfail.2017.10.008.
19. Ansari AA, Fett JD, Carraway RE, et al. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. *Clinical Reviews in Allergy & Immunology*. 2002;23(3):301-324. doi:10.1385/CRIAI:23:3:301.
20. Biteker M, Ilhan E, Biteker G, Duman D, Bozkurt B. Delayed recovery in peripartum cardiomyopathy: an indication for long-term follow-up and sustained therapy. *European Journal of Heart Failure*. 2012;14(8):895-901. doi:10.1093/eurjhf/hfs080.
21. Forster O, Hilfiker-Kleiner D, Ansari AA, et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. *European Journal of Heart Failure*. 2008;10(9):861-868. doi:10.1016/j.ejheart.2008.06.010.
22. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. *Lancet*. 2006;368(9536):687-693. doi:10.1016/S0140-6736(06)69253-2.
23. Biteker M. Peripartum cardiomyopathy: current state of knowledge, new developments and future directions. *Current Heart Failure Reports*. 2013;10(4): 1-6. doi:10.1007/s11897-013-0156-4.
24. Lampert MB, Hibbard J, Weinert L, Briller J, Lindheimer M, Lang RM. Peripartum heart failure associated with prolonged tocolytic therapy. *American Journal of Obstetrics and Gynecology*. 1993;168(2):493-495. doi:10.1016/S0002-9378(11)90752-7.
25. Blauwet LA, Libhaber E, Forster O, et al. Predictors of outcome in 176 South African patients with peripartum cardiomyopathy. *Heart*. 2013;99(5):308-313. doi:10.1136/heartjnl-2012-302634.
26. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Heart failure with preserved ejection fraction: ESC guidelines. *European Heart Journal*. 2016;37(19): 1526-1546. doi:10.1093/eurheartj/ehw128.
27. Pillarisetti J, Kondur A, Alani A, et al. Peripartum cardiomyopathy: predictors of recovery and current state of implantable cardioverter-defibrillator use. *Journal of the American College of Cardiology*. 2014;63(25 Pt A):2831-2839. doi:10.1016/j.jacc.2014.03.032.
28. Hilfiker-Kleiner D, Haghikia A, Berliner D, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. *European Heart Journal*. 2017;38(35): 2671-2679. doi:10.1093/eurheartj/ehx416.
29. Bello N, Mosca L. Epidemiology of peripartum cardiomyopathy in the United States: a systematic review. *American Journal of Obstetrics and Gynecology*. 2018; 219(1):91-100. doi:10.1016/j.ajog.2018.01.026.
30. Irizarry OC, Levine LD, Lewey J, Boyer T, Riis V, Elovitz MA. Comparison of postpartum versus nonpostpartum cardiomyopathy in a multiethnic cohort. *The American Journal of Cardiology*. 2017;119(12):1968-1972. doi:10.1016/j.amjcard.2017.03.028.

31. McNamara DM, Elkayam U, Alharethi R, et al. Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). *Journal of the American College of Cardiology*. 2015;66(8):905-914. doi:10.1016/j.jacc.2015.06.1309.
32. Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. *New England Journal of Medicine*. 2001;344(21):1567-1571. doi:10.1056/NEJM200105243442104.
33. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. *Cell*. 2007;128(3):589-600. doi:10.1016/j.cell.2006.12.036.
34. Hilfiker-Kleiner D, Meyer GP, Schieffer E, et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. *Journal of the American College of Cardiology*. 2007;50(24):2354-2355. doi:10.1016/j.jacc.2007.07.084.
35. Sliwa K, Förster O, Libhaber E, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. *European Heart Journal*. 2006;27(4):441-446. doi:10.1093/eurheartj/ehi481.
36. Karaye KM, Lindmark K, Henein MY. One-year survival in Nigerians with peripartum cardiomyopathy. *Heart Views*. 2013;14(4):160-166. doi:10.4103/1995-705X.129248.
37. Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. *Circulation*. 2005;111(16):2050-2055. doi:10.1161/01.CIR.0000162478.36652.7E.
38. Damasceno A, Mayosi BM, Sani M, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries: results of the Sub-Saharan Africa Survey of Heart Failure. *Archives of Internal Medicine*. 2012;172(18):1386-1394. doi:10.1001/archinternmed.2012.3310.
39. Ramaraj R, Sorrell VL. Peripartum cardiomyopathy: causes, diagnosis, and treatment. *Cleveland Clinic Journal of Medicine*. 2009;76(5):289-296. doi:10.3949/ccjm.76a.08069.
40. Sliwa K, Skudicky D, Bergemann A, Candy G, Puren A, Sareli P. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. *Journal of the American College of Cardiology*. 2000;35(3):701-705. doi:10.1016/s0735-1097(99)00620-6.
41. Karaye KM, Lindmark K, Henein MY. Relation between duration of symptoms and outcome in peripartum cardiomyopathy. *International Journal of Cardiology*. 2013;163(3):326-328. doi:10.1016/j.ijcard.2011.09.087.
42. Hilfiker-Kleiner D, Struman I, Hoch M, Podewski E, Sliwa K. Prolactin and autoimmunity in postpartum cardiomyopathy. *Autoimmunity Reviews*. 2007;6(2):77-79. doi:10.1016/j.autrev.2006.07.003.
43. Ansari AA, African American Heart Failure Trial (A-HeFT) Investigators. Should patients with peripartum cardiomyopathy receive an implantable cardioverter-defibrillator? *The American Journal of Cardiology*. 2014;113(2):415-416. doi:10.1016/j.amjcard.2013.09.028.
44. Fett JD. Peripartum cardiomyopathy: a puzzle closer to solution. *Journal of Cardiac Failure*. 2010;16(7):593-595. doi:10.1016/j.cardfail.2010.04.004.
45. Blauwet LA, Cooper LT. Diagnosis and Management of Peripartum Cardiomyopathy. *Heart*. 2011;97(23):1970-1981. doi:10.1136/heartjnl-2011-300349.
46. Halkein J, Tabruyn SP, Ricke-Hoch M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. *The Journal of Clinical Investigation*. 2013;123(5):2143-2154. doi:10.1172/JCI64365.

47. Haghikia A, Ricke-Hoch M, Stapel B, et al. Gorham-Stout disease - On the role of interleukin-6 in bone metabolism: Letter to the editor. *Zeitschrift für Rheumatologie*. 2015;74(5):485-488. doi:10.1007/s00393-015-1520-7.
48. Biteker M, Ilhan E, Biteker G, Duman D, Bozkurt B. Delayed recovery in peripartum cardiomyopathy: An indication for long-term follow-up and sustained therapy. *European Journal of Heart Failure*. 2012;14(8):895-901. doi:10.1093/eurjhf/hfs080.
49. Baughman KL. The Diagnosis of Peripartum Cardiomyopathy. *Heart Failure Clinics*. 2005;1(3):363-366. doi:10.1016/j.hfc.2005.07.004.
50. Haghikia A, Kaya Z, Schwab J, et al. Evidence of autoantibodies to cardiac troponin I in peripartum cardiomyopathy. *Journal of the American College of Cardiology*. 2011;57(6):E2275. doi:10.1016/S0735-1097(11)62276-2.
51. Sliwa K, Petrie MC, Hilfiker-Kleiner D, et al. Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. *European Journal of Heart Failure*. 2018;20(6):951-962. doi:10.1002/ejhf.1173.
52. Gentry MB, Dias JK, Luis A, Patel R, Thornton J, Reed GL. African-American women have a higher risk for developing peripartum cardiomyopathy. *Journal of the American College of Cardiology*. 2010;55(7):654-659. doi:10.1016/j.jacc.2009.09.042.
53. Kolte D, Khera S, Aronow WS, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. *Journal of the American Heart Association*. 2014;3(3):e001056. doi:10.1161/JAHA.114.001056.
54. Elkayam U, Jalnapurkar S, Barakkat MN, et al. Pregnancy-associated acute myocardial infarction: a review of contemporary experience in 150 cases between 2006 and 2011. *Circulation*. 2014;129(16):1695-1702. doi:10.1161/CIRCULATIONAHA.113.002073.